BioSpace News Archive

Verastem Oncology today announced it has entered into a credit facility with Oxford Finance LLC for up to $150 million that is designed to primarily support the continued development, commercial preparation and potential launches of VS-6766 and defactinib.

enVVeno Medical Corporation today provided a corporate update and reported financial results for the fourth quarter and year-end of 2021.

Protagonist Therapeutics (Nasdaq: PTGX) today announced the appointment of Asif Ali as Executive Vice President and Chief Financial Officer (CFO).

Since its formation as a wholly independent company in late 2020, Spine Innovations has continued to expand sales of its ESP spinal disc replacements, with more than 20,000 prostheses successfully implanted in patients around the world.

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, announced financial results for the full-year ended December 31, 2021 and recent corporate highlights.

Provention Bio, Inc. today announced positive results from the final analysis of its first-in-human PROVENT study of PRV-101, a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate targeting all key CVB strains associated with type 1 diabetes (T1D) autoimmunity.

Loki Therapeutics today announced the publications of research in the journal, “Science Translational Medicine”, demonstrating the potential of AWAKE-LM-TT in the treatment of pancreatic cancer

CyanVac LLC and its subsidiary, Blue Lake Biotechnology, Inc., today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for BLB-201, an intranasal vaccine for the prevention of respiratory syncytial virus (RSV) infection.

Global Parents for Eczema Research and GlobalSkin - International Alliance of Dermatology Patient Organizations announced the winners of the “Big Ideas for Eczema Challenge” contest that generated worldwide interest and received 70 submissions from 11 countries.

Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced that its poster, “Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C Evaluated Over 13 Hours in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study,” will be presented at the Academy of Managed Care Pharmacy (AMCP) on March 30, 2022, in Chicago, IL